News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
Content Sharing
SKB BIO (06990.HK) to Present Multiple Innovative Drug Research Results at ASCO Annual Meeting in US
SKB BIO (06990.HK) announced that it will present multiple company-led clinical research results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held ...
Reset
Send
The window will close in 5 seconds
SKB BIO (06990.HK) to Present Multiple Innovative Drug Research Results at ASCO Annual Meeting in US
Close
Recommend
3
Positive
1
Negative
0
 
 

SKB BIO (06990.HK)  -11.400 (-2.404%)    Short selling $53.99M; Ratio 9.430%   announced that it will present multiple company-led clinical research results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 29 to June 2 in Chicago, Illinois, the US. Among them, two pivotal studies have been selected for oral presentations in the metastatic non-small cell lung cancer session, including the TROP2-targeting antibody-drug conjugate (ADC) sac-TMT (Jiatelai) and the next-generation selective RET inhibitor A400/EP0031 (Ningtelai).

SKB BIO is currently quoted at HKD474.2, up 4.54%, with a turnover of 435,700 shares, involving HKD210 million. (jl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-26 16:25.)

Related NewsNomura Raises SKB BIO (06990.HK) TP to HKD544.42; Encouraging Lung Cancer Data

Auto-translated by AI
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.